A Soave1, R Dahlem1, J Hansen1, L Weisbach1, S Minner2, O Engel1, L A Kluth1, F K Chun1, S F Shariat3, M Fisch1, M Rink4. 1. University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany. 2. University Medical Center Hamburg-Eppendorf, Department of Pathology, Hamburg, Germany. 3. University Medical Center Vienna, Department of Urology, Vienna, Austria. 4. University Medical Center Hamburg-Eppendorf, Department of Urology, Hamburg, Germany. Electronic address: mrink@uke.uni-hamburg.de.
Abstract
INTRODUCTION: Controversial findings regarding gender-specific oncological outcomes of urothelial carcinoma of the bladder (UCB) have recently been reported. The aim of this study was to analyze gender-specific outcomes using a stage-adjusted approach in a homogenous, contemporary radical cystectomy (RC) cohort. MATERIAL AND METHODS: We prospectively collected data of 517 UCB patients treated with RC and pelvic lymphadenectomy without neoadjuvant chemotherapy at our institution between 1996 and 2010. Stage-adjusted uni- and multivariable Cox regression models analyzed the association of gender with disease recurrence, cancer-specific mortality and overall survival. RESULTS: In total, 398 (77%) patients were male and 119 (23%) were female. Compared to men, women were more likely to have advanced tumor stages (p = 0.017), nodal metastasis (p = 0.047) and received more frequently adjuvant chemotherapy (p = 0.009). At a median follow-up of 44 months, there was no statistical difference in disease recurrence, cancer-specific mortality and overall survival between both genders when analyzed as a group. In stage-adjusted analyses, only women with non-invasive UCB were more likely to die of UCB compared to the male counterparts (p = 0.013). In gender-specific multivariable analyses that adjusted for standard clinico-pathologic features, pathologic tumor stage was an independent predictor for disease recurrence (p-values ≤0.047) and cancer-specific mortality (p-values ≤0.049), respectively. CONCLUSION: Women present with more aggressive tumor biologic features at RC, however this did not translate into inferior outcomes compared to men in stage-specific analyses in our cohort. Tumor stage is the most important factor influencing the course of disease in both genders. Validation of our findings is warranted in a larger cohort.
INTRODUCTION: Controversial findings regarding gender-specific oncological outcomes of urothelial carcinoma of the bladder (UCB) have recently been reported. The aim of this study was to analyze gender-specific outcomes using a stage-adjusted approach in a homogenous, contemporary radical cystectomy (RC) cohort. MATERIAL AND METHODS: We prospectively collected data of 517 UCB patients treated with RC and pelvic lymphadenectomy without neoadjuvant chemotherapy at our institution between 1996 and 2010. Stage-adjusted uni- and multivariable Cox regression models analyzed the association of gender with disease recurrence, cancer-specific mortality and overall survival. RESULTS: In total, 398 (77%) patients were male and 119 (23%) were female. Compared to men, women were more likely to have advanced tumor stages (p = 0.017), nodal metastasis (p = 0.047) and received more frequently adjuvant chemotherapy (p = 0.009). At a median follow-up of 44 months, there was no statistical difference in disease recurrence, cancer-specific mortality and overall survival between both genders when analyzed as a group. In stage-adjusted analyses, only women with non-invasive UCB were more likely to die of UCB compared to the male counterparts (p = 0.013). In gender-specific multivariable analyses that adjusted for standard clinico-pathologic features, pathologic tumor stage was an independent predictor for disease recurrence (p-values ≤0.047) and cancer-specific mortality (p-values ≤0.049), respectively. CONCLUSION:Women present with more aggressive tumor biologic features at RC, however this did not translate into inferior outcomes compared to men in stage-specific analyses in our cohort. Tumor stage is the most important factor influencing the course of disease in both genders. Validation of our findings is warranted in a larger cohort.
Authors: Oliver Engel; Armin Soave; Sven Peine; Luis A Kluth; Marianne Schmid; Shahrokh F Shariat; Roland Dahlem; Margit Fisch; Michael Rink Journal: World J Urol Date: 2015-03-18 Impact factor: 4.226
Authors: Mohammad Abufaraj; Shahrokh Shariat; Marco Moschini; Florian Rohrer; Kyriaki Papantoniou; Elizabeth Devore; Monica McGrath; Xuehong Zhang; Sarah Markt; Eva Schernhammer Journal: Int J Epidemiol Date: 2020-04-01 Impact factor: 7.196
Authors: Leslie K Ballas; Stephanie Navarro; Chunqiao Luo; Croix C Fossum; Albert Farias; Siamak Daneshmand; Susan Groshen Journal: Cancer Med Date: 2021-03-28 Impact factor: 4.452